Monthly Prescribing Reference

NexoBrid Approval Expanded to Include Pediatric Burn Patients

NexoBrid is a topically administered, bromelain-based biological product containing a sterile mixture of proteolytic enzymes. The Food and Drug Administration (FDA) has expanded the approval of ...
Medscape

Bromelain and Antibiotics Aid Crans-Montana Burn Care

Experience from Crans-Montana shows how rapid eschar removal and targeted antimicrobials can reduce the surgical burden and ...
Nasdaq

MediWound: FDA To Review NexoBrid SBLA For Removal Of Eschar In Pediatric Patients

(RTTNews) - MediWound Ltd. (MDWD) announced the FDA has completed their filing review and accepted a supplement to the NexoBrid biologics license application for the removal of eschar in pediatric ...
Business Insider

Vericel Announces U.S. Commercial Availability of NexoBrid® (anacaulase-bcdb) for the Treatment of Severe Thermal Burns in Adults

Full commercial launch of NexoBrid marks important first step to becoming the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns NexoBrid ...
Seeking Alpha

Vericel Announces Publication of Positive Results from Phase 3 Debride and Protect (DETECT) Study of Thermal Burn Patients Treated with NexoBrid

CAMBRIDGE, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the recent ...
Monthly Prescribing Reference

Severe Burn Therapy NexoBrid Gets FDA Approval

Credit: Getty Images. NexoBrid is a topically administered, bromelain-based biological product containing a sterile mixture of proteolytic enzymes. The Food and Drug Administration (FDA) has approved ...
Healio

Botanical drug may outperform standard of care for treatment of severe thermal burns

Please provide your email address to receive an email when new articles are posted on . Phase 3 data shows NexoBrid allows for the early complete eschar removal in more than 90% of patients. This ...
CNN

Vericel Announces Submission of Biologics License Application to the FDA for NexoBrid for the Treatment of Severe Thermal Burns

CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration ...
Seeking Alpha

Vericel Announces U.S. Commercial Availability of NexoBrid® (anacaulase-bcdb) for the Treatment of Severe Thermal Burns in Adults

CAMBRIDGE, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the U.S.